JP7791196B2 - キナーゼ阻害剤としてのインダゾール化合物 - Google Patents
キナーゼ阻害剤としてのインダゾール化合物Info
- Publication number
- JP7791196B2 JP7791196B2 JP2023540770A JP2023540770A JP7791196B2 JP 7791196 B2 JP7791196 B2 JP 7791196B2 JP 2023540770 A JP2023540770 A JP 2023540770A JP 2023540770 A JP2023540770 A JP 2023540770A JP 7791196 B2 JP7791196 B2 JP 7791196B2
- Authority
- JP
- Japan
- Prior art keywords
- ethoxy
- pyridyl
- indazol
- dichloro
- indazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025243767A JP2026048777A (ja) | 2020-12-30 | 2025-12-09 | キナーゼ阻害剤としてのインダゾール化合物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063132031P | 2020-12-30 | 2020-12-30 | |
| US63/132,031 | 2020-12-30 | ||
| US202163216879P | 2021-06-30 | 2021-06-30 | |
| US63/216,879 | 2021-06-30 | ||
| PCT/US2021/065679 WO2022147246A1 (en) | 2020-12-30 | 2021-12-30 | Indazole compounds as kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025243767A Division JP2026048777A (ja) | 2020-12-30 | 2025-12-09 | キナーゼ阻害剤としてのインダゾール化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024502433A JP2024502433A (ja) | 2024-01-19 |
| JP2024502433A5 JP2024502433A5 (cg-RX-API-DMAC7.html) | 2025-01-09 |
| JP7791196B2 true JP7791196B2 (ja) | 2025-12-23 |
Family
ID=80168316
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023540770A Active JP7791196B2 (ja) | 2020-12-30 | 2021-12-30 | キナーゼ阻害剤としてのインダゾール化合物 |
| JP2025243767A Pending JP2026048777A (ja) | 2020-12-30 | 2025-12-09 | キナーゼ阻害剤としてのインダゾール化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025243767A Pending JP2026048777A (ja) | 2020-12-30 | 2025-12-09 | キナーゼ阻害剤としてのインダゾール化合物 |
Country Status (16)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| MX2023007793A (es) | 2020-12-30 | 2023-09-22 | Tyra Biosciences Inc | Compuestos de indazol como inhibidores de cinasas. |
| WO2024104922A1 (en) | 2022-11-14 | 2024-05-23 | Ascendis Pharma Growth Disorders A/S | Method of improving skeletal muscle function |
| IL317558A (en) * | 2022-06-29 | 2025-02-01 | Tyra Biosciences Inc | Indazole compounds |
| AU2023300357A1 (en) * | 2022-06-29 | 2025-01-09 | Tyra Biosciences, Inc. | Polymorphic compounds and uses thereof |
| AU2023334178A1 (en) | 2022-08-30 | 2025-03-13 | Tyra Biosciences, Inc. | Methods of treating solid tumors having activating fgfr3 gene alterations |
| WO2024137742A1 (en) | 2022-12-20 | 2024-06-27 | Blueprint Medicines Corporation | Compounds and compositions as fgfr3 degraders and uses thereof |
| WO2024138112A1 (en) * | 2022-12-22 | 2024-06-27 | Tyra Biosciences, Inc. | Indazole compounds |
| AU2023420301A1 (en) * | 2022-12-30 | 2025-06-12 | Asieris Pharmaceuticals (Shanghai) Co., Ltd. | Pyrazole fused ring compound, and preparation method therefor and use thereof |
| KR20250162619A (ko) | 2023-03-20 | 2025-11-18 | 아센디스 파마 그로우쓰 디스오더스 에이/에스 | 연골무형성증을 가진 인간 대상에서의 흉요추 변형의 치료 방법 |
| CN119306723B (zh) * | 2023-07-13 | 2026-04-10 | 长春金赛药业有限责任公司 | 吲唑类fgfr2/3选择性抑制剂、药物组合物及其应用 |
| CN121013846A (zh) * | 2023-07-21 | 2025-11-25 | 长春金赛药业有限责任公司 | 成纤维细胞生长因子受体抑制剂、药物组合物及其应用 |
| EP4750781A1 (en) | 2023-07-27 | 2026-06-03 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | New map4k1 inhibitors |
| EP4780816A1 (en) * | 2023-09-18 | 2026-07-29 | 3H Pharmaceuticals Co., Ltd. | Fgfr inhibitors and methods of use thereof |
| TW202519212A (zh) | 2023-09-22 | 2025-05-16 | 美商泰拉生物科學公司 | 組合治療療法 |
| AU2024400764A1 (en) * | 2023-12-15 | 2026-07-09 | Tyra Biosciences, Inc. | Indazole compounds for the treatment of cancer |
| WO2025170959A1 (en) | 2024-02-05 | 2025-08-14 | Tyra Biosciences, Inc. | Combination of the fgfr 3 inhibitor tyra-300 and a nectin-4 targeting agent-drug conjugate for use in the treatment of cancer |
| WO2025199217A1 (en) | 2024-03-19 | 2025-09-25 | Tyra Biosciences, Inc. | Pharmaceutical compositions |
| WO2026020109A1 (en) * | 2024-07-19 | 2026-01-22 | Tyra Biosciences, Inc. | Combination treatment comprising a fgfr3 inhibitor and a pd-1/pd-l1 inhibitor for use in the treatment of cancer |
| WO2026035809A1 (en) * | 2024-08-06 | 2026-02-12 | Tyra Biosciences, Inc. | Indazole compounds for the treatment of cancer |
| CN122255133A (zh) * | 2024-09-24 | 2026-06-23 | 上海辉棵生物医药有限公司 | 新fgfr3抑制剂化合物 |
| WO2026143225A1 (en) | 2024-12-27 | 2026-07-02 | Tyra Biosciences, Inc. | Therapies with ppar agonists and fgfr3 inhibitors |
| WO2026165305A1 (en) * | 2025-01-31 | 2026-08-06 | Tyra Biosciences, Inc. | Fgfr3 inhibitors for use in a method of treating children with achondroplasia |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013538875A (ja) | 2010-10-05 | 2013-10-17 | イーライ リリー アンド カンパニー | 結晶((r)−(e)−2−(4−(2−(5−(1−(3,5−ジクロロピリジン−4−イル)エトキシ)−1h−インダゾール−3−イル)ビニル)−1h−ピラゾール−1−イル)エタノールおよびfgfr阻害剤としての使用 |
| CN106317023A (zh) | 2015-07-10 | 2017-01-11 | 中国科学院上海药物研究所 | 吲唑类化合物的制备方法和用途 |
| JP2018531218A (ja) | 2015-08-07 | 2018-10-25 | ハルビン チェンバオ ファーマシューティカル カンパニー リミテッド | Fgfr及びvegfr阻害剤であるビニル化合物 |
| US20210094935A1 (en) | 2019-10-01 | 2021-04-01 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
Family Cites Families (146)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3657744A (en) | 1970-05-08 | 1972-04-25 | Univ Minnesota | Method for fixing prosthetic implants in a living body |
| US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| JPS62135830A (ja) | 1985-12-09 | 1987-06-18 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料及びその処理方法 |
| JPS62135835A (ja) | 1985-12-09 | 1987-06-18 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料の処理方法 |
| JPS62135832A (ja) | 1985-12-09 | 1987-06-18 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料の処理方法 |
| JPS62135834A (ja) | 1985-12-09 | 1987-06-18 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料の処理方法 |
| JPS62136654A (ja) | 1985-12-10 | 1987-06-19 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料の処理方法 |
| JPS62136651A (ja) | 1985-12-10 | 1987-06-19 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料の処理方法 |
| JPS62136650A (ja) | 1985-12-11 | 1987-06-19 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料及びその処理方法 |
| US5350395A (en) | 1986-04-15 | 1994-09-27 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
| US5061273A (en) | 1989-06-01 | 1991-10-29 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
| US5040548A (en) | 1989-06-01 | 1991-08-20 | Yock Paul G | Angioplasty mehtod |
| US4748982A (en) | 1987-01-06 | 1988-06-07 | Advanced Cardiovascular Systems, Inc. | Reinforced balloon dilatation catheter with slitted exchange sleeve and method |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| GB8808433D0 (en) | 1988-04-11 | 1988-05-11 | Merck Sharp & Dohme | Therapeutic agents |
| CA1322628C (en) | 1988-10-04 | 1993-10-05 | Richard A. Schatz | Expandable intraluminal graft |
| US6344053B1 (en) | 1993-12-22 | 2002-02-05 | Medtronic Ave, Inc. | Endovascular support device and method |
| US5292331A (en) | 1989-08-24 | 1994-03-08 | Applied Vascular Engineering, Inc. | Endovascular support device |
| US5674278A (en) | 1989-08-24 | 1997-10-07 | Arterial Vascular Engineering, Inc. | Endovascular support device |
| US5041453A (en) | 1990-05-30 | 1991-08-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Quinolinyl-benzoheterobicyclic derivatives as antagonists of leukotriene D4 |
| CA2249615A1 (en) | 1996-04-03 | 1997-10-09 | Robert Gomez | Inhibitors of farnesyl-protein transferase |
| US6063930A (en) | 1996-04-03 | 2000-05-16 | Merck & Co., Inc. | Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors |
| CN1281441A (zh) | 1997-11-04 | 2001-01-24 | 辉瑞产品公司 | 以在pde4抑制剂中的儿茶酚的吲唑生物等排物置换为基础的治疗活性化合物 |
| TR200001234T2 (tr) | 1997-11-04 | 2000-08-21 | Pfizer Products Inc. | Terapötik aktif bileşiklerde katelkolün indazol biyoisoster değişimi. |
| EP1046631A1 (en) | 1999-04-19 | 2000-10-25 | Rolic AG | Liquid crystalline compounds |
| GB9908934D0 (en) | 1999-04-19 | 1999-06-16 | Rolic Ag | Liquid crystalline compounds |
| YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| WO2002083648A1 (fr) | 2001-04-16 | 2002-10-24 | Eisai Co., Ltd. | Nouveau compose a base de 1h-indazole |
| US6995144B2 (en) | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
| CN1656079A (zh) | 2002-05-31 | 2005-08-17 | 卫材株式会社 | 吡唑化合物和含有该化合物的药物组合物 |
| US7186716B2 (en) | 2002-08-12 | 2007-03-06 | Sugen, Inc. | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors |
| CN102584813B (zh) | 2003-05-14 | 2016-07-06 | Ngc药物公司 | 化合物及其在调节淀粉样蛋白β中的用途 |
| JP2007510629A (ja) | 2003-10-22 | 2007-04-26 | イーライ リリー アンド カンパニー | 新規mch受容体アンタゴニスト |
| WO2005060958A1 (en) | 2003-12-19 | 2005-07-07 | Kalypsys, Inc. | (5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes |
| US7635698B2 (en) | 2004-12-29 | 2009-12-22 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| WO2006071875A1 (en) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| CA2598725C (en) | 2005-03-04 | 2010-10-26 | Merck & Co., Inc. | Fused aromatic compounds having anti-diabetic activity |
| WO2007044085A2 (en) | 2005-05-19 | 2007-04-19 | Xenon Pharmaceuticals Inc. | Heteroaryl compounds and their uses as therapeutic agents |
| WO2007050124A1 (en) | 2005-05-19 | 2007-05-03 | Xenon Pharmaceuticals Inc. | Fused piperidine derivatives and their uses as therapeutic agents |
| WO2007058626A1 (en) | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Indazole compounds |
| US8008481B2 (en) | 2006-03-31 | 2011-08-30 | Ericsson Anna M | Indazole compounds |
| DE102006030479A1 (de) | 2006-07-01 | 2008-03-20 | Merck Patent Gmbh | Indazolderivate |
| US20080027052A1 (en) | 2006-07-10 | 2008-01-31 | Sharon Moe | Methods for treating cystic kidney disease |
| US20110008347A1 (en) | 2006-12-01 | 2011-01-13 | Agency For Science ,Technology And Research | Cancer-related protein kinases |
| EP2134683A2 (en) | 2007-02-12 | 2009-12-23 | Intermune, Inc. | Novel inhibitors hepatitis c virus replication |
| EP2074114B1 (en) | 2007-04-25 | 2013-03-06 | Exelixis, Inc. | Pyrimidinones as casein kinase ii (ck2) modulators |
| EP2155187B1 (en) | 2007-05-07 | 2016-05-25 | Merck Sharp & Dohme Corp. | Method of treatment using fused aromatic compounds having anti-diabetic activity |
| GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| JP2010111624A (ja) | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ttk阻害作用を有するインダゾール誘導体 |
| WO2010065668A1 (en) | 2008-12-03 | 2010-06-10 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| AR074760A1 (es) | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
| AU2009330233A1 (en) | 2008-12-22 | 2011-07-07 | Merck Sharp & Dohme Corp. | Gamma secretase modulators |
| WO2010075273A1 (en) | 2008-12-23 | 2010-07-01 | Schering Corporation | Bicyclic heterocycle derivatives and methods of use thereof |
| WO2010088518A2 (en) | 2009-01-31 | 2010-08-05 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| TW201038569A (en) | 2009-02-16 | 2010-11-01 | Abbott Gmbh & Co Kg | Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy |
| US20120040977A1 (en) | 2009-02-23 | 2012-02-16 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| US8455516B2 (en) | 2010-01-15 | 2013-06-04 | Touro University | HIV-1 fusion inhibitors and methods |
| KR101483215B1 (ko) | 2010-01-29 | 2015-01-16 | 한미약품 주식회사 | 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체 |
| EP2368876A1 (en) | 2010-03-01 | 2011-09-28 | Sanofi | Derivatives of aminoindanes, their preparation and their application in therapeutics |
| US20130079348A1 (en) | 2010-03-03 | 2013-03-28 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| JP5763937B2 (ja) | 2010-03-10 | 2015-08-12 | Agcセイミケミカル株式会社 | 液晶化合物、その製造方法、液晶組成物および液晶電気光学素子 |
| CN103221404B (zh) | 2010-05-13 | 2015-12-16 | 安姆根有限公司 | 可用作pde10抑制剂的不饱和氮杂环化合物 |
| HUE052110T2 (hu) | 2010-07-29 | 2021-04-28 | Rigel Pharmaceuticals Inc | AMPK-t aktiváló heterociklusos vegyületek és alkalmazásuk |
| WO2012068589A2 (en) | 2010-11-19 | 2012-05-24 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| TWI450891B (zh) | 2010-12-29 | 2014-09-01 | Dev Center Biotechnology | 新穎微管蛋白抑制劑 |
| WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| SG194625A1 (en) | 2011-05-23 | 2013-12-30 | Sanofi Sa | Process for the preparation of deuterated compounds containing n-alkyl groups |
| CN102243505B (zh) | 2011-07-07 | 2013-08-14 | 矽力杰半导体技术(杭州)有限公司 | 一种低失调、快速响应的电压控制电流源、控制方法以及应用其的电源电路 |
| JP6036693B2 (ja) | 2011-08-05 | 2016-11-30 | アステラス製薬株式会社 | 新規fgfr4変異体の検出法 |
| EP2744807A4 (en) | 2011-08-15 | 2015-03-04 | Intermune Inc | COMPOUNDS AS LYSOPHOSPHIC ACID RECEPTOR ANTAGONISTS |
| WO2013030138A1 (en) | 2011-09-01 | 2013-03-07 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine kinase inhibitors |
| DK2753605T3 (da) | 2011-09-09 | 2019-06-17 | Lantheus Medical Imaging Inc | Sammensætninger, fremgangsmåder, og systemer til syntesen og anvendelsen af billeddannelsesmidler |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| US9254288B2 (en) | 2012-05-07 | 2016-02-09 | The Translational Genomics Research Institute | Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof |
| CN103420906B (zh) * | 2012-05-21 | 2015-09-09 | 南京圣和药业股份有限公司 | 新型酪氨酸蛋白激酶抑制剂 |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| US9013997B2 (en) | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
| EP4223770A3 (en) | 2012-11-05 | 2023-10-18 | Foundation Medicine, Inc. | Novel fusion molecules and uses thereof |
| TW201437200A (zh) | 2013-01-15 | 2014-10-01 | Intermune Inc | 溶血磷脂酸受體拮抗劑 |
| CA2898326C (en) | 2013-01-18 | 2022-05-17 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
| KR101648141B1 (ko) | 2013-06-11 | 2016-08-12 | 제일모직 주식회사 | 화합물, 이를 포함하는 유기 광전자 소자 및 상기 유기 광전자 소자를 포함하는 표시장치 |
| JP6084292B2 (ja) | 2013-07-18 | 2017-02-22 | 大鵬薬品工業株式会社 | Fgfr阻害剤耐性癌の治療薬 |
| US10323285B2 (en) | 2013-09-09 | 2019-06-18 | Nantomics, Llc | Proteomics analysis and discovery through DNA and RNA sequencing, systems and methods |
| US20150087673A1 (en) | 2013-09-26 | 2015-03-26 | Rigel Pharmaceuticals, Inc. | Methods for using and biomarkers for ampk-activating compounds |
| CA2924843A1 (en) | 2013-09-27 | 2015-04-02 | Allergan, Inc. | Compounds and methods for skin repair |
| EP3082802B1 (en) | 2013-12-03 | 2020-02-26 | Iomet Pharma Ltd. | Tryptophan-2,3-dioxygenase (tdo) and/or indolamine-2,3-dioxygenase (ido) inhibitors and their use |
| IL274464B2 (en) | 2013-12-11 | 2023-08-01 | Accuragen Holdings Ltd | Preparations and methods for the detection of rare sequence variants |
| WO2015099127A1 (ja) | 2013-12-27 | 2015-07-02 | 中外製薬株式会社 | Fgfrゲートキーパー変異遺伝子およびそれを標的とする医薬 |
| WO2015103527A1 (en) | 2014-01-06 | 2015-07-09 | The Scripps Research Institute | Modulators of rev-erb |
| US20160340742A1 (en) | 2014-02-04 | 2016-11-24 | Mayo Foundation For Medical Education And Research | Method of Identifying Tyrosine Kinase Receptor Rearrangements in Patients |
| WO2015150900A2 (en) | 2014-03-31 | 2015-10-08 | Debiopharm International Sa | Fgfr fusions |
| US10351527B2 (en) | 2014-04-09 | 2019-07-16 | The University Of British Columbia | Binding function 3 (BF3) site compounds as therapeutics and methods for their use |
| JP6788577B2 (ja) | 2014-05-09 | 2020-11-25 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 液晶媒体およびそれを含む高周波数素子 |
| NZ726874A (en) | 2014-05-19 | 2018-03-23 | Merial Inc | Anthelmintic compounds |
| US10100042B2 (en) | 2014-08-08 | 2018-10-16 | Merck Sharp & Dohme Corp. | [5,6]—fused bicyclic antidiabetic compounds |
| CN107427524A (zh) | 2014-08-28 | 2017-12-01 | 翁科埃斯克斯有限公司 | 利用包含噻吩并三唑并二氮杂*化合物的药物组合物治疗急性髓细胞白血病或急性淋巴性白血病的方法 |
| WO2016074762A1 (en) | 2014-11-11 | 2016-05-19 | Merck Patent Gmbh | Bimesogenic compounds and mesogenic media |
| JP2018027019A (ja) | 2014-11-26 | 2018-02-22 | 国立研究開発法人国立がん研究センター | 胆道がんにおける新規治療標的融合遺伝子 |
| AU2015371312B2 (en) | 2014-12-24 | 2022-01-27 | Genentech, Inc. | Therapeutic, diagnostic and prognostic methods for cancer of the bladder |
| WO2016139227A1 (en) | 2015-03-03 | 2016-09-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fgfr3 antagonists |
| KR101663277B1 (ko) | 2015-03-30 | 2016-10-06 | 주식회사 녹십자 | TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물 |
| WO2016172631A2 (en) | 2015-04-24 | 2016-10-27 | President And Fellows Of Harvard College | Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof |
| WO2017066705A1 (en) | 2015-10-14 | 2017-04-20 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use against stress granules |
| JP2018531266A (ja) | 2015-10-22 | 2018-10-25 | セルビタ エス.エー. | ピリドン誘導体およびキナーゼ阻害剤としてのその使用 |
| WO2017150586A1 (ja) | 2016-03-02 | 2017-09-08 | Jnc株式会社 | 積層体、電子機器、積層体の製造方法 |
| WO2017150587A1 (ja) | 2016-03-02 | 2017-09-08 | Jnc株式会社 | 低熱膨張部材用組成物、低熱膨張部材、電子機器、低熱膨張部材の製造方法 |
| WO2017161028A1 (en) | 2016-03-16 | 2017-09-21 | Kura Oncology, Inc. | Substituted inhibitors of menin-mll and methods of use |
| US20190177617A1 (en) | 2016-05-12 | 2019-06-13 | Merck Patent Gmbh | Bimesogenic compounds and mesogenic media |
| CA3035105C (en) | 2016-08-30 | 2023-09-12 | Dow Global Technologies Llc | Method of attenuating concentration of acrolein |
| JP6589795B2 (ja) | 2016-09-27 | 2019-10-16 | 信越化学工業株式会社 | スルホニウム塩、レジスト組成物及びパターン形成方法 |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| WO2019018795A1 (en) | 2017-07-20 | 2019-01-24 | Yumanity Therapeutics | COMPOUNDS AND USES THEREOF |
| WO2019036562A1 (en) | 2017-08-18 | 2019-02-21 | Saint Louis University | ERR INVERSE AGONISTS |
| CN109400522B (zh) | 2017-08-18 | 2023-04-28 | 上海轶诺药业有限公司 | 一种具有pd-l1抑制活性的化合物、其制备方法及用途 |
| WO2019209948A1 (en) | 2018-04-25 | 2019-10-31 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| JP2021536458A (ja) | 2018-09-04 | 2021-12-27 | マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. | アリール炭化水素レセプター・アンタゴニスト及び使用方法 |
| KR102127006B1 (ko) | 2018-12-06 | 2020-06-25 | 한국생산기술연구원 | 피리미딘계 작용기 함유 단분자 화합물, 상기 화합물의 광가교물을 포함한 유기물층 및 이를 포함하는 유기전자소자 |
| WO2020139748A1 (en) | 2018-12-28 | 2020-07-02 | Cedars-Sinai Medical Center | Methods of treating inflammatory bowel diseases that target ripk2 |
| CN111434655A (zh) | 2019-01-15 | 2020-07-21 | 武汉朗来科技发展有限公司 | 溶血磷脂酸受体拮抗剂及其制备方法 |
| IN201941011265A (cg-RX-API-DMAC7.html) * | 2019-03-22 | 2020-09-25 | ||
| BR112021022897A2 (pt) | 2019-05-14 | 2022-01-25 | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Inibidor contendo derivado bicíclico, método de preparação do mesmo e uso do mesmo |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CN112409331B (zh) | 2019-08-21 | 2024-02-20 | 上海翰森生物医药科技有限公司 | 杂环类衍生物抑制剂、其制备方法和应用 |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| CN112812014B (zh) | 2019-11-15 | 2024-05-10 | 石家庄诚志永华显示材料有限公司 | 化合物、液晶组合物、液晶显示器 |
| WO2021104305A1 (zh) | 2019-11-26 | 2021-06-03 | 上海翰森生物医药科技有限公司 | 含氮多环类衍生物抑制剂、其制备方法和应用 |
| TW202136253A (zh) | 2019-12-19 | 2021-10-01 | 美商卡司馬療法公司 | Trpml調節劑 |
| US20230128972A1 (en) | 2020-01-31 | 2023-04-27 | Atomwise Inc. | Anat Inhibitors and Methods of Use Thereof |
| EP4103278A1 (en) | 2020-02-12 | 2022-12-21 | Curadev Pharma Pvt. Ltd. | Small molecule sting antagonists |
| WO2021178780A1 (en) | 2020-03-06 | 2021-09-10 | ESCAPE Bio, Inc. | Indazoles and azaindazoles as lrrk2 inhibitors |
| US20230140941A1 (en) | 2020-03-13 | 2023-05-11 | University Of Maryland, Baltimore | Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors |
| MX2022013861A (es) | 2020-05-06 | 2023-02-22 | Servier Lab | Nuevos inhibidores macrociclicos de la quinasa de lrrk2. |
| MX2023007793A (es) | 2020-12-30 | 2023-09-22 | Tyra Biosciences Inc | Compuestos de indazol como inhibidores de cinasas. |
| WO2022194976A1 (en) | 2021-03-18 | 2022-09-22 | Les Laboratoires Servier | Macrocyclic lrrk2 kinase inhibitors |
| CA3211347A1 (en) | 2021-03-19 | 2022-09-22 | Erika Araujo | Indazole based compounds and associated methods of use |
| WO2023279041A1 (en) * | 2021-06-30 | 2023-01-05 | Tyra Biosciences, Inc. | Indazole compounds |
| EP4504722A4 (en) | 2022-04-04 | 2026-03-18 | Brenig Therapeutics Inc | LRRK2 INHIBITORS |
| AU2023300357A1 (en) | 2022-06-29 | 2025-01-09 | Tyra Biosciences, Inc. | Polymorphic compounds and uses thereof |
| IL317558A (en) | 2022-06-29 | 2025-02-01 | Tyra Biosciences Inc | Indazole compounds |
| AU2023334178A1 (en) | 2022-08-30 | 2025-03-13 | Tyra Biosciences, Inc. | Methods of treating solid tumors having activating fgfr3 gene alterations |
-
2021
- 2021-12-30 MX MX2023007793A patent/MX2023007793A/es unknown
- 2021-12-30 US US18/259,422 patent/US12264149B2/en active Active
- 2021-12-30 WO PCT/US2021/065679 patent/WO2022147246A1/en not_active Ceased
- 2021-12-30 IL IL304014A patent/IL304014A/en unknown
- 2021-12-30 KR KR1020237024903A patent/KR20230152654A/ko active Pending
- 2021-12-30 JP JP2023540770A patent/JP7791196B2/ja active Active
- 2021-12-30 PE PE2023001961A patent/PE20240687A1/es unknown
- 2021-12-30 CA CA3205986A patent/CA3205986A1/en active Pending
- 2021-12-30 EP EP21852113.6A patent/EP4271673A1/en active Pending
- 2021-12-30 AU AU2021411587A patent/AU2021411587B2/en active Active
- 2021-12-30 TW TW110149633A patent/TWI923663B/zh active
- 2021-12-30 CR CR20230325A patent/CR20230325A/es unknown
-
2023
- 2023-06-26 EC ECSENADI202348136A patent/ECSP23048136A/es unknown
- 2023-06-26 ZA ZA2023/06559A patent/ZA202306559B/en unknown
- 2023-06-30 CO CONC2023/0008689A patent/CO2023008689A2/es unknown
- 2023-06-30 CL CL2023001951A patent/CL2023001951A1/es unknown
-
2024
- 2024-02-22 US US18/584,440 patent/US12071428B2/en active Active
-
2025
- 2025-02-03 US US19/043,650 patent/US20250340533A1/en active Pending
- 2025-12-09 JP JP2025243767A patent/JP2026048777A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013538875A (ja) | 2010-10-05 | 2013-10-17 | イーライ リリー アンド カンパニー | 結晶((r)−(e)−2−(4−(2−(5−(1−(3,5−ジクロロピリジン−4−イル)エトキシ)−1h−インダゾール−3−イル)ビニル)−1h−ピラゾール−1−イル)エタノールおよびfgfr阻害剤としての使用 |
| CN106317023A (zh) | 2015-07-10 | 2017-01-11 | 中国科学院上海药物研究所 | 吲唑类化合物的制备方法和用途 |
| JP2018531218A (ja) | 2015-08-07 | 2018-10-25 | ハルビン チェンバオ ファーマシューティカル カンパニー リミテッド | Fgfr及びvegfr阻害剤であるビニル化合物 |
| US20210094935A1 (en) | 2019-10-01 | 2021-04-01 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023007793A (es) | 2023-09-22 |
| IL304014A (en) | 2023-08-01 |
| US20240208941A1 (en) | 2024-06-27 |
| ZA202306559B (en) | 2025-09-25 |
| CO2023008689A2 (es) | 2023-09-29 |
| US20250340533A1 (en) | 2025-11-06 |
| JP2024502433A (ja) | 2024-01-19 |
| AU2021411587B2 (en) | 2024-10-10 |
| ECSP23048136A (es) | 2023-09-29 |
| US12264149B2 (en) | 2025-04-01 |
| CL2023001951A1 (es) | 2023-12-01 |
| KR20230152654A (ko) | 2023-11-03 |
| EP4271673A1 (en) | 2023-11-08 |
| CA3205986A1 (en) | 2022-07-07 |
| CR20230325A (es) | 2023-12-11 |
| US12071428B2 (en) | 2024-08-27 |
| US20240109865A1 (en) | 2024-04-04 |
| WO2022147246A1 (en) | 2022-07-07 |
| JP2026048777A (ja) | 2026-03-17 |
| AU2021411587A1 (en) | 2023-07-06 |
| TWI923663B (zh) | 2026-05-01 |
| PE20240687A1 (es) | 2024-04-10 |
| TW202241906A (zh) | 2022-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12071428B2 (en) | Indazole compounds as kinase inhibitors | |
| CN104428299B (zh) | 5-氮杂吲唑化合物及其使用方法 | |
| US20240316022A1 (en) | Indazole compounds | |
| KR20240127910A (ko) | Sos1 억제제 및 항암제를 포함하는 암 치료용 약학 조성물 | |
| CN104125959B (zh) | 作为btk活性的抑制剂的杂芳基吡啶酮和氮杂‑吡啶酮化合物 | |
| CN103987707B (zh) | 吡唑‑4‑基‑杂环基‑甲酰胺化合物以及使用方法 | |
| JP2025535046A (ja) | Kras g12c変異タンパク質の複素環阻害剤及びその使用 | |
| JP2023538060A (ja) | 二環化合物、それを含む組成物、及びそれらの使用 | |
| KR20250040643A (ko) | 인다졸 화합물 | |
| CN116583283B (zh) | Cdk抑制剂及其作为药物的用途 | |
| WO2025129014A1 (en) | Indazole compounds for the treatment of cancer | |
| ES3039638T3 (en) | Melanocortin 4 receptor antagonists and uses thereof | |
| US20240190849A1 (en) | Aminopyrimidine compounds and methods of their use | |
| CN116761798A (zh) | 作为激酶抑制剂的吲唑类化合物 | |
| WO2024138112A1 (en) | Indazole compounds | |
| CN119546604A (zh) | 作为hpk1抑制剂的吡啶并[3,2-d]嘧啶 | |
| HK40100302A (en) | Indazole compounds as kinase inhibitors | |
| EA050408B1 (ru) | Соединение индазола в качестве ингибиторов киназы | |
| HK40119556A (en) | Indazole compounds | |
| WO2026035809A1 (en) | Indazole compounds for the treatment of cancer | |
| WO2025222097A1 (en) | Indazole-based protac degraders and their anticancer activity | |
| OA21024A (en) | Spiro compounds as melanocortin 4 receptor antagonists and uses thereof. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241225 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241225 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20251016 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20251111 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20251211 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7791196 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |